Patents by Inventor Basel Hasan Taha
Basel Hasan Taha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11759565Abstract: A drug delivery device includes a housing defining a shell, a container, a drive mechanism, a needle assembly having first and second ends, a fluid flow connection, and a flow adapter, each of which is at least partially disposed within the housing. The container has first and second ends and an inner volume to contain a medicament to be administered to a user. The drive mechanism is adapted to exert a force to urge the medicament out the second end of the container. The fluid flow connection is coupled to the second end of the container and the first end of the needle assembly and is adapted to allow the medicament to flow from the container to the needle assembly. The flow adapter includes at least one protrusion for generating a minor head loss to the medicament flowing within the fluid flow connection and helps to reduce variations of injection rates due to variations in drug product viscosities.Type: GrantFiled: September 26, 2018Date of Patent: September 19, 2023Assignee: AMGEN INC.Inventors: Carl Conrath, Ali Nekouzadeh, Basel Hasan Taha
-
Publication number: 20230201461Abstract: Systems and methods are disclosed for processing sensor data collected by a drug delivery device with an external computing device. The drug delivery device may include a reservoir and a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient. The drug delivery device may further include one or more sensors configured to generate sensor data representative of a condition and/or operational state of the drug delivery device, and a communication module configured to transmit information to the external computing device. The external computing device may process the information received from the drug delivery device according to information stored in a memory of the external computing device to determine the condition or the operational state of the drug delivery device and/or generate instructional or informational prompts to be displayed to a user or patient.Type: ApplicationFiled: February 17, 2023Publication date: June 29, 2023Inventors: Adam B. McCullough, Basel Hasan Taha, Jimmie L. Ward, Christopher R. Folk, Steven William Badelt, Ferry Tamtoro, Huaying Yang, Mark Ka Lai Lee, Desheng Yin, Scott R. Gibson, Donald Busby, Peter V. Shultz, Keith P. Kogler
-
Publication number: 20230098606Abstract: Devices and methods are disclosed for assisting a user of a drug delivery device with an application executing on a mobile computing device. The mobile computing device may receive information from the drug delivery device related to its condition and/or operation and subsequently select an informational and/or instructional prompt to be displayed to the user based on the received information. The mobile computing device may also generate a display in the application including the selected informational prompt and/or the instructional prompt. Accordingly, the user of the drug delivery device can be guided through the drug delivery process in real time, thereby reducing the likelihood of improper or incomplete use of the drug delivery device.Type: ApplicationFiled: September 8, 2022Publication date: March 30, 2023Inventors: Adam B. McCullough, Basel Hasan Taha, Jimmie L. Ward, Steven William Badelt, Ferry Tamtoro, Huaying Yang, Mark Ka Lai Lee, Desheng Yin, Scott R. Gibson, Donald Busby, Peter V. Shultz, Keith P. Kogler
-
Publication number: 20220257862Abstract: A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further include one or more sensors coupled to the drug delivery device, and a controller coupled to the one or more sensors and the one or more controllable elements. The controller may be configured to use the one or more sensors to determine a condition or an operational state of the drug delivery device. Furthermore, the controller may be configured to control the controllable element based on the condition or the operational state of the drug delivery device and/or identity information stored in a memory onboard the device. A method for use with a drug delivery device is also disclosed.Type: ApplicationFiled: November 23, 2021Publication date: August 18, 2022Inventors: Adam B. McCullough, Ferry Tamtoro, Huaying Yang, Mark Ka Lai Lee, Desheng Yin, Scott R. Gibson, Donald Busby, Peter V. Shultz, Keith P. Kogler, Basel Hasan Taha, Jimmie L. Ward, Christopher R. Folk, Steven William Badelt
-
Publication number: 20220218900Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.Type: ApplicationFiled: March 7, 2022Publication date: July 14, 2022Inventors: Scott R. Gibson, Sheldon B, Moberg, Basel Hasan Taha, Margaux Frances Boyaval, Mark A. Destefano, John C. Love, Ian B. Hanson, Paul F. Bente, IV, Matthew J. Clemente, Rajan Ramaswamy, Daniel S. Codd, Scott Beaver, Kevin L. Bokelman, Sean M. O'connor, Robert Decker, Gautam N. Shetty, Ryan M. Agard, Nicholas J. Ciccarelli, Daniel Davenport
-
Patent number: 11266777Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.Type: GrantFiled: February 13, 2017Date of Patent: March 8, 2022Assignee: AMGEN INC.Inventors: Scott R. Gibson, Sheldon B. Moberg, Basel Hasan Taha, Margaux Frances Boyaval, Mark A. Destefano, John C. Love, Ian B. Hanson, Paul F. Bente, IV, Matthew J. Clemente, Rajan Ramaswamy, Daniel S. Codd, Scott Beaver, Kevin L. Bokelman, Sean M. O'connor, Robert Decker, Gautam N. Shetty, Ryan M. Agard, Nicholas J. Ciccarelli, Daniel Davenport
-
Publication number: 20220031939Abstract: Methods, devices, and components are provided to reduce tissue resistive pressure during a subcutaneous drug delivery operation by increasing the size of the injection cavity by partially retracting the drug delivery member after inserting the drug delivery member to a subcutaneous position. The drug delivery devices described herein include a motor operably coupled to a drug delivery member. The motor can be selectively activated by a controller to retract the drug delivery member a predetermined distance to relieve pressure in an injection cavity in a patient. A force sensor can provide the controller with a drug delivery member insertion force. The controller can then estimate a tissue resistive pressure based on the drug delivery member insertion force and determine the predetermined distance for the partial drug delivery member retraction based on the tissue resistive pressure.Type: ApplicationFiled: October 14, 2019Publication date: February 3, 2022Inventors: Ali Nekouzadeh, Carl Conrath, Scott Robert Gibson, Basel Hasan Taha
-
Publication number: 20220031953Abstract: Methods, devices, and components are provided to reduce tissue resistive pressure during a subcutaneous drug delivery operation by increasing the size of the injection cavity by partially retracting the drug delivery member after inserting the drug delivery member to a subcutaneous position. The drug delivery devices described herein include a resilient member that interacts between stationary and moveable components of the drug delivery device. The drug delivery device include drives to move the stationary and moveable components relative to one another to insert a drug delivery member to a subcutaneous depth within a patient and to dispense a drug to the injection cavity in the patient. The resilient member is deformed during the operations or is pre-deformed and the stored energy of the resilient member in the deformed state then acts on the stationary and moveable components to partially retract the drug delivery member to relieve pressure in the injection region.Type: ApplicationFiled: October 22, 2019Publication date: February 3, 2022Inventors: Ali Nekouzadeh, Carl Conrath, Basel Hasan Taha
-
Patent number: 11213624Abstract: A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further include one or more sensors coupled to the drug delivery device, and a controller coupled to the one or more sensors and the one or more controllable elements. The controller may be configured to use the one or more sensors to determine a condition or an operational state of the drug delivery device. Furthermore, the controller may be configured to control the controllable element based on the condition or the operational state of the drug delivery device and/or identity information stored in a memory onboard the device. A method for use with a drug delivery device is also disclosed.Type: GrantFiled: April 8, 2020Date of Patent: January 4, 2022Assignee: AMGEN INC.Inventors: Adam B. McCullough, Ferry Tamtoro, Huaying Yang, Mark Ka Lai Lee, Desheng Yin, Scott R. Gibson, Donald Busby, Peter V. Shultz, Keith P. Kogler, Basel Hasan Taha, Jimmie L. Ward, Christopher R. Folk, Steven William Badelt
-
Patent number: 11213620Abstract: Methods, devices, and components are provided to reduce tissue resistive pressure during a subcutaneous drug delivery operation by increasing the size of the injection cavity by partially retracting the drug delivery member after inserting the drug delivery member to a subcutaneous position. The drug delivery devices described herein include a magnetic actuator operably coupled to a primary container assembly including a drug delivery member. Power can be selectively provided to the magnetic actuator by a controller to retract the drug delivery member a predetermined distance to relieve pressure in an injection cavity in a patient. A force sensor can provide the controller with a drug delivery member insertion force. The controller can then estimate a tissue resistive pressure based on the drug delivery member insertion force and determine the predetermined distance for the drug delivery member retraction based on the tissue resistive pressure.Type: GrantFiled: October 7, 2019Date of Patent: January 4, 2022Assignee: AMGEN INC.Inventors: Ali Nekouzadeh, Carl Conrath, Scott Robert Gibson, Basel Hasan Taha
-
Publication number: 20210402083Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.Type: ApplicationFiled: July 28, 2021Publication date: December 30, 2021Inventors: Scott R. Gibson, Sheldon B. Moberg, Basel Hasan Taha, Margaux Frances Boyaval, Mark A. Destefano, Lawton Laurence, John C. Love, Ian B. Hanson, Paul F. Bente, IV, Matthew J. Clemente, Antonio Ubach, Rajan Ramaswamy, Daniel S. Codd, Scott Beaver, Kevin L. Bokelman, Ian P. Dardani, Sean M. O'connor, Danielle Feldman
-
Patent number: 11207460Abstract: A drug delivery system includes a storage container defining one or more storage compartments and having at least one container sensor coupled thereto, a container condition change mechanism coupled to the storage container for imparting a change on one or more conditions of the one or more storage compartments, at least one drug delivery device adapted to deliver a drug to a user and adapted to be at least partially disposed within one or more of the one or more storage compartments, at least one delivery device sensor, a delivery device condition change mechanism coupled to the drug delivery device, and a controller coupled to the storage container. The storage container may be adapted to hold a number of drug delivery devices within a number of sealable storage compartments. The container sensor is adapted to sense a condition of the storage container, and the delivery device sensor is adapted to sense a condition of the at least one drug delivery device.Type: GrantFiled: December 14, 2016Date of Patent: December 28, 2021Assignee: AMGEN INC.Inventors: Ferry Tamtoro, Huaying Yang, Scott Robert Gibson, Donald Busby, Peter V. Shultz, Basel Hasan Taha, Adam B. McCullough
-
Publication number: 20210308376Abstract: Methods, devices, and components are provided to reduce tissue resistive pressure during a subcutaneous drug delivery operation by increasing the size of the injection cavity by partially retracting the drug delivery member after inserting the drug delivery member to a subcutaneous position. The drug delivery devices described herein include a magnetic actuator operably coupled to a primary container assembly including a drug delivery member. Power can be selectively provided to the magnetic actuator by a controller to retract the drug delivery member a predetermined distance to relieve pressure in an injection cavity in a patient. A force sensor can provide the controller with a drug delivery member insertion force. The controller can then estimate a tissue resistive pressure based on the drug delivery member insertion force and determine the predetermined distance for the drug delivery member retraction based on the tissue resistive pressure.Type: ApplicationFiled: October 7, 2019Publication date: October 7, 2021Inventors: Ali Nekouzadeh, Carl Conrath, Scott Robert Gibson, Basel Hasan Taha
-
Patent number: 11129936Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.Type: GrantFiled: April 7, 2017Date of Patent: September 28, 2021Assignee: AMGEN INC.Inventors: Scott R. Gibson, Sheldon B. Moberg, Basel Hasan Taha, Margaux Frances Boyaval, Mark A. Destefano, Lawton Laurence, John C. Love, Ian B. Hanson, Paul F. Bente, IV, Matthew J. Clemente, Antonio Ubach, Rajan Ramaswamy, Daniel S. Codd, Scott Beaver, Kevin L. Bokelman, Ian P. Dardani, Sean M. O'connor, Danielle Feldman
-
Publication number: 20200353169Abstract: A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further include one or more sensors coupled to the drug delivery device, and a controller coupled to the one or more sensors and the one or more controllable elements. The controller may be configured to use the one or more sensors to determine a condition or an operational state of the drug delivery device. Furthermore, the controller may be configured to control the controllable element based on the condition or the operational state of the drug delivery device and/or identity information stored in a memory onboard the device. A method for use with a drug delivery device is also disclosed.Type: ApplicationFiled: April 8, 2020Publication date: November 12, 2020Inventors: Adam B. McCullough, Ferry Tamtoro, Huaying Yang, Mark Ka Lai Lee, Desheng Yin, Scott R. Gibson, Donald Busby, Peter V. Shultz, Keith P. Kogler, Basel Hasan Taha, Jimmie L. Ward, Christopher R. Folk, Steven William Badelt
-
Publication number: 20200316291Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.Type: ApplicationFiled: April 7, 2017Publication date: October 8, 2020Inventors: Scott Robert Gibson, Sheldon B. Moberg, Basel Hasan Taha, Margaux Frances Boyaval, Mark A. Destefano, Lawton Laurence, John C. Love, Ian B. Hanson, Paul F. Bente, IV, Matthew J. Clemente, Antonio Ubach, Rajan Ramaswamy, Daniel S. Codd, Scott Beaver, Kevin L. Bokelman, Ian P. Dardani, Sean M. O'connor, Danielle Feldman
-
Publication number: 20200297927Abstract: A drug delivery device includes a housing defining a shell, a container, a drive mechanism, a needle assembly having first and second ends, a fluid flow connection, and a flow adapter, each of which is at least partially disposed within the housing. The container has first and second ends and an inner volume to contain a medicament to be administered to a user. The drive mechanism is adapted to exert a force to urge the medicament out the second end of the container. The fluid flow connection is coupled to the second end of the container and the first end of the needle assembly and is adapted to allow the medicament to flow from the container to the needle assembly. The flow adapter includes at least one protrusion for generating a minor head loss to the medicament flowing within the fluid flow connection and helps to reduce variations of injection rates due to variations in drug product viscosities.Type: ApplicationFiled: September 26, 2018Publication date: September 24, 2020Inventors: Carl Conrath, Ali Nekouzadeh, Basel Hasan Taha
-
Publication number: 20200289740Abstract: A drug delivery system includes a storage container defining one or more storage compartments and having at least one container sensor coupled thereto, a container condition change mechanism coupled to the storage container for imparting a change on one or more conditions of the one or more storage compartments, at least one drug delivery device adapted to deliver a drug to a user and adapted to be at least partially disposed within one or more of the one or more storage compartments, at least one delivery device sensor, a delivery device condition change mechanism coupled to the drug delivery device, and a controller coupled to the storage container. The storage container may be adapted to hold a number of drug delivery devices within a number of sealable storage compartments. The container sensor is adapted to sense a condition of the storage container, and the delivery device sensor is adapted to sense a condition of the at least one drug delivery device.Type: ApplicationFiled: December 14, 2016Publication date: September 17, 2020Inventors: Ferry Tamtoro, Huaying Yang, Scott Robert Gibson, Donald Busby, Peter V. Shultz, Basel Hasan Taha, Adam B. McCullough
-
Patent number: 10646652Abstract: A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further include one or more sensors coupled to the drug delivery device, and a controller coupled to the one or more sensors and the one or more controllable elements. The controller may be configured to use the one or more sensors to determine a condition or an operational state of the drug delivery device. Furthermore, the controller may be configured to control the controllable element based on the condition or the operational state of the drug delivery device and/or identity information stored in a memory onboard the device. A method for use with a drug delivery device is also disclosed.Type: GrantFiled: June 3, 2015Date of Patent: May 12, 2020Assignee: AMGEN INC.Inventors: Adam B. McCullough, Ferry Tamtoro, Huaying Yang, Mark Ka Lai Lee, Desheng Yin, Scott R. Gibson, Donald Busby, Peter V. Shultz, Keith P. Kogler, Basel Hasan Taha, Jimmie L. Ward, Christopher R. Folk, Steven William Badelt
-
Publication number: 20190022306Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.Type: ApplicationFiled: February 13, 2017Publication date: January 24, 2019Applicant: Amgen Inc.Inventors: Scott R. GIBSON, Sheldon B. MOBERG, Basel Hasan TAHA, Margaux Frances BOYAVAL, Mark A. DESTEFANO, John C. LOVE, Ian B. HANSON, Paul F. BENTE, IV, Matthew J. CLEMENTE, Rajan RAMASWAMY, Daniel S. CODD, Scott BEAVER, Kevin L. BOKELMAN, Sean M. O'CONNOR, Robert DECKER, Gautam N. SHETTY, Ryan M. AGARD, Nicholas J. CICCARELLI, Daniel DAVENPORT